Pharmaceutical

CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia.
Read the original article

Tags:

Previous Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

Next Article

BNT-325 by Duality Biologics (Shanghai) for Metastatic Ovarian Cancer: Likelihoo...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Bristol drug reduces reliance on transfusions for people with chronic blood disorder

STAT+: Bristol drug reduces reliance on transfusions fo...

May 25, 2023

STAT+: NIH releases data showing more clinical trial sponsors are reporting results, but most miss deadlines

STAT+: NIH releases data showing more clinical trial sp...

Mar 30, 2023

Opinion: Where do we go from here on digital therapeutics?

Opinion: Where do we go from here on digital therapeutics?

Feb 1, 2024